Immucell (IUL) AI Stock Analysis

1 Followers

Immucell

(Frankfurt:IUL)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Strong Revenue and Customer GrowthBroad-based sales and distributor-volume growth indicates stronger product adoption and commercial execution, not merely isolated customer activity. Continued expansion can improve operating leverage, strengthen channel relationships, and provide a durable base for scaling the company’s cattle-health portfolio.

Negative Factors

Thin and Volatile ProfitabilityAlthough the company has returned to profit, modest margins leave limited protection against cost increases or execution setbacks. The history of losses and volatile earnings makes it harder to establish that the recent improvement is durable rather than an early-stage recovery.

Immucell (IUL) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 97.63M
Dividend Yield: ―
Average Volume (3M): 77
Price to Earnings (P/E): 53.8
Beta (1Y): 0.86
Revenue Growth: 12.81%
EPS Growth: -26.68%
Country: Germany
Employees: 73
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

Immucell Business Overview & Revenue Model

Company Description

ImmuCell Corporation functions as an animal health enterprise, specializing in the creation, manufacturing, and commercialization of offerings aimed at improving the vitality and output of dairy and beef cattle, serving both the U.S. domestic market...

Immucell Earnings Call Summary

Earnings Call Date:Nov 12, 2026(Q3-2026)|% Change Since:0.00%|Next Earnings Date:Feb 23, 2027

Earnings Call SentimentPositive

The call was strongly positive, characterized by 46% third-quarter revenue growth, improved gross margin, a return to profitability, higher manufacturing output, strong distributor and Tri-Shield growth, and progress on capacity expansion. The company also reported challenges, including historical contamination-related supply issues, rising colostrum-sourcing prices, higher operating expenses, and the unsuccessful Re-Tain development program, but these were outweighed by the reported operating and financial improvements.

Positive Updates

Strong Third-Quarter Revenue Growth

Third-quarter 2026 product sales were approximately $8 million, up 46% compared with the third quarter of 2025. Management attributed the increase to restored product availability, a favorable domestic calf market, increased commercial activity, improved supply-chain management, and the absence of distributor restocking headwinds that affected the prior-year quarter.

Negative Updates

Re-Tain Development Halted

The company stopped investing in Re-Tain after its contract manufacturer was unable to obtain GMP approval from the FDA. Recent clinical trials were unsuccessful in supporting incremental or new claims, Re-Tain activities remain paused, and management said it is not planning further investment in the product.

Company Guidance

Management expects calf values to remain strong in 2027 and 2028, believes it can meet customer demand with improved yield management until the new drying capacity expansion project is completed, and expects the new freeze dryer planned for installation in the first half of 2027 to “triple or so” freeze-drying capacity; the liquids processing expansion is expected to be completed by the end of 2027, with the overall project remaining on track to the original $8 million overall budget.

Immucell Risk Analysis

Immucell disclosed 38 risk factors in its most recent earnings report. Immucell reported the most risks in the "Finance & Corporate" category.

Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

0 New Risks

Immucell Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:IUL against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PDSB	57Neutral	$102.91M	-1.36	-708.20%	―	―	32.24%
INO	55Neutral	$273.47M	-1.80	-9999.00%	―	63.93%	68.94%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ARCT	47Neutral	$243.26M	-2.70	-46.79%	―	-74.84%	-25.04%
RANI	42Neutral	$73.21M	-2.78	-96.44%	―	448.67%	76.29%

* Healthcare Sector Average

Performance Comparison

DE:IUL and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:IUL	Immucell	9.05	4.41	95.04%
INO	Inovio Pharmaceuticals	1.43	-0.55	-27.78%
ARCT	Arcturus Therapeutics	8.36	1.60	23.67%
XBIT	XBiotech Inc.	1.96	-0.51	-20.65%
PDSB	Pds Biotechnology	0.87	0.09	12.23%
RANI	Rani Therapeutics Holdings, Inc. Class A	0.53	-1.41	-72.89%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Immucell AI Stock Analysis